EUCTR2017-000347-41-NL进行中（未招募）1 期
Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours - Extended use of ModraDoc006/r
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histological or cytological proof of cancer
- •2. Patients who might benefit from a weekly (oral) docetaxel regime as judged by the treating oncologist.
- •3. Patients who received treatment with ModraDoc006/r with acceptable safety (as judged by the PI; for criteria see below in section 3 of inegibility criteria) in phase I trials with ModraDoc006/r, including (but not limited to) the N15FED (food-interaction study), N16AED (absorption-excretion study), N16DOL (normal or impaired liver function). A maximum delay of 21 days between the last dose in the previous phase I trial and the first dose in the N17DEX is allowed.
- •4. Age = 18 years
- •5. WHO performance status of 0, 1 or 2;
- •6. Minimal acceptable laboratory values defined as:
- •a. ANC of = 1.5 x 109 /L
- •b. Platelet count of = 100 x 109 /L
- •c. Renal function as defined by serum creatinine equal or lower than 3.0 x ULN
- •d. Hepatic function as defined by serum bilirubin equal or lower than 5.0 x ULN, ALAT and ASAT equal or lower than 5.0 x ULN, except for patients who have been treated in the N16DOL study.
- •7. Negative pregnancy test (urine/serum) for female patients with childbearing potential, assessed at the screeningsvisit for the previous phase I trial with ModraDoc006/r treatment
- •8. Able and willing to swallow oral medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •1. Concomitant use of MDR and CYP3A modulating drugs such as Ca+-entry blockers (verapamil, dihydropyridines), cyclosporine, quinidine, quinine, tamoxifen, megestrol and grapefruit juice, concomitant use of HIV medications; other protease inhibitors, (non) nucleoside analoga, St. Johns wort or macrolide antibiotics.
- •2. Symptomatic brain metastases or leptomeningeal metastases. Patients with brain metastases are allowed if they received adequate treatment, are asymptomatic in the absence of corticosteroid therapy and anticonvulsant therapy for at least 6 weeks. Radiotherapy for brain metastases must have been completed at least 4 weeks prior to start of study treatment.
- •3. Clinically significant safety issues during previous therapy with ModraDoc006/r as judged by the PI, which cannot be solved by dose reduction and/or treatment delay.
- •4. Unreliable contraceptive methods. Both men and women using ModraDoc006/r must agree to use a reliable contraceptive method throughout the treatment
- •5. Oncolytic therapy or any treatment with investigational drugs other than ModraDoc006/r between the completion of the phase I trial with ModraDoc006/r and the start of extended use of ModraDoc006/r Palliative limited radiation is allowed, but must have been completed at least 4 weeks prior to start of extended use.
研究者
相似试验
已完成
不适用
Weekly administration of (bi-)daily Oral Docetaxel in combination with Ritonavirmalignancy10027655cancerNL-OMON39193Antoni van Leeuwenhoek Ziekenhuis48
已完成
不适用
Weekly administration of oral docetaxel in combination with ritonavir for the treatment of a variety of tumour typesCancerISRCTN32770468The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/ALH) (Netherlands)78
招募中
不适用
Weekly administration of Oral Docetaxel in combination with Ritonaviradvanced cancer10027656NL-OMON39153Antoni van Leeuwenhoek Ziekenhuis100
进行中（未招募）
不适用
Continuous vs intermittent weekly docetaxel in the elderly patient with advanced and hormone-refractory prostate cancer: a randomized phase II study - NDAdvanced and hormone-refractory prostate cancerMedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2008-001632-13-ITEGA ITALIANA PER LA LOTTA CONTRO I TUMORI
招募中
不适用
Safety and efficacy of monthly administration of darbepoetin alfa compared to the methoxy polyethylene glycol-epoetin beta in the treatment of anemia associated with chronic kidney disease in non-dialysis patientsDiseases of The genitoruinary systemKCT0003999Soon Chun Hyang University Hospital Bucheon40